Results 121 to 130 of about 255,650 (266)

Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System

Annals of Neurology, EarlyView.
Objective Tau is widely studied in neurodegeneration, yet most work has focused on canonical brain tau isoforms. A longer isoform, “big tau,” produced by inclusion of exon 4a, is expressed in the peripheral nervous system (PNS) and central nervous system (CNS) regions.
Rama Krishna Koppisetti, Nicolas R. Barthélemy, Kanta Horie, Cindy V. Ly, Kaleigh F. Roberts, Srinivas Koutarapu, Richard J. Perrin, Erin E. Franklin, Chiara Pedicone, Joshua Orrick, Justin Melendez, Timothy M. Miller, Chihiro Sato, Nupur Ghoshal, Alison M. Goate, Celeste M. Karch, Randall J. Bateman, Soumya Mukherjee   +17 more
wiley   +1 more source

Prevalence and factors associated with microvascular and macrovascular diabetes complications in adult Ugandans: A systematic review and meta-analysis. [PDF]

PLoS One
Kibirige D, Olum R, Turyamureeba W, Morgan B, Kyazze AP, Nsubuga Y, Okot J, Lumu W, Bongomin F.   +8 more
europepmc   +1 more source

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3

Annals of Neurology, EarlyView.
Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock‐In Atxn3Q300/Q6, we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation.
Juan P. Mato, John M. Hayes, Jacen Emerson, Maeha Sridharan, Toluwani Adelaja, Arsal Naeem, Alexandra F. Putka, Hayley S. McLoughlin   +7 more
wiley   +1 more source

Diabetic neuropathy is associated with increased long-term morbidity and revision risk following lumbar laminectomy or laminotomy. [PDF]

J Spine Surg
Jawich B, Harhash T, Elnaggar A, Almaat A, Saad J, Hilo AK, Alqasmi H, Forbes T, Vaidya R.   +8 more
europepmc   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Perioperative Visual Loss After Spine Surgery: A Case-Based Review of Posterior Ischemic Optic Neuropathy. [PDF]

Orthop Rev (Pavia)
Nguyen A, Hasoon J, Li T, Robinson CL, Nguyen V.   +4 more
europepmc   +1 more source

Endoscopic Proximal Hamstring Repairs Remain Safe and Beneficial With High Patient Satisfaction at a Minimum of 6‐Year Follow‐Up

Arthroscopy, EarlyView.
Purpose To evaluate midterm outcomes of endoscopic proximal hamstring repair in a previously established cohort. Methods A retrospective study design was used for a midterm (minimum 6 years) follow‐up time. Patients completed the questionnaires over the phone or electronically on REDCap after consent. The questionnaires included the modified Harris Hip
Shannon N. Greenwood, Temitope Adebayo, Emily K. Reinke, Amanda N. Fletcher, Brian D. Lewis, Elizabeth J. Scott, Richard Charles Mather   +6 more
wiley   +1 more source

Gut microbiota dysbiosis as a novel pathogenic factor of diabetic peripheral neuropathy

Journal of Diabetes Investigation
Naoko Niimi, Kazunori Sango
doaj   +1 more source

Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate. [PDF]

J Peripher Nerv Syst
Sloan G, Azmi S, Eid S, Ferdousi M, Røikjer J, Kender Z, D'Onofrio L, Karlafti E, Callaghan B, Perkins BA.   +9 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source